[1] Wolf S A, Boddeke H W, Kettenmann H. Microglia in physiology and disease[J]. Annu Rev Physiol, 2017, 79: 619-643. [2] Joers V, Tansey M G, Mulas G, et al. Microglial phenotypes in Parkinson's disease and animal models of the disease[J]. Prog Neurobiol, 2017, 155: 57-75. [3] Zhang T, Gong X L, Hu G Z, et al. EP2-PKA signaling is suppressed by triptolide in lipopolysaccharide-induced microglia activation[J]. J Neuroinflammation, 2015, 12: 50. [4] Green D R, Oguin T H, Martinez J. The clearance of dying cells: table for two[J]. Cell Death Differ, 2016, 23(6): 915-926. [5] Emmrich J V, Neher J J, Boehm-Sturm P, et al. Stage 1 registered report: effect of deficient phagocytosis on neuronal survival and neurological outcome after temporary middle cerebral artery occlusion (tMCAo)[J]. F1000Res, 2017, 6: 1827. [6] Deczkowska A, Amit I, Schwartz M. Microglial immune checkpoint mechanisms[J]. Nat Neurosci, 2018, 21(6): 779-786. [7] Wang L, Liu Y, Yan S X, et al. Disease progression-dependent expression of CD200R1 and CX3CR1 in mouse models of Parkinson's disease[J]. Aging Dis, 2020, 11(2): 254-268. [8] Wang L, Gong X L, Liu Y, et al. CD200 maintains the region-specific phenotype of microglia in the midbrain and its role in Parkinson's disease[J]. Glia, 2020, 68(9): 1874-1890. [9] Gordon S. Phagocytosis: an immunobiologic process[J]. Immunity, 2016, 44(3): 463-475. [10] Arandjelovic S, Ravichandran K S. Phagocytosis of apoptotic cells in homeostasis[J]. Nat Immunol, 2015, 16(9): 907-917. [11] Li C X, Zhao B, Lin C Z, et al. TREM2 inhibits inflammatory responses in mouse microglia by suppressing the PI3K/NF-κB signaling[J]. Cell Biol Int, 2019, 43(4): 360-372. [12] Kawabe K, Takano K, Moriyama M, et al. Lipopolysaccharide-stimulated transglutaminase 2 expression enhances endocytosis activity in the mouse microglial cell line BV-2[J]. Neuroimmunomodulation, 2015, 22(4): 243-249. [13] Lin Y C, Uang H W, Lin R J, et al. Neuroprotective effects of glyceryl nonivamide against microglia-like cells and 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells[J]. J Pharmacol Exp Ther, 2007, 323(3): 877-887. [14] Aramillo Irizar P, Schäuble S, Esser D, et al. Transcriptomic alterations during ageing reflect the shift from cancer to degenerative diseases in the elderly[J]. Nat Commun, 2018, 9(1): 327. [15] Tremblay M E, Cookson M R, Civiero L. Glial phagocytic clearance in Parkinson's disease[J]. Mol Neurodegener, 2019, 14(1): 16. [16] 袁惠莉,宫晓丽,范征,等.远志皂苷对脂多糖诱导的帕金森病模型大鼠的作用及机制研究[J]. 首都医科大学学报,2020,41(6):914-922. [17] Hernangómez M, Carrillo-Salinas F J, Mecha M, et al. Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system[J]. Curr Pharm Des, 2014, 20(29): 4707-4722. [18] Lyons A, Minogue A M, Jones R S, et al. Analysis of the impact of CD200 on phagocytosis[J]. Mol Neurobiol, 2017, 54(7): 5730-5739. [19] Varnum M M, Kiyota T, Ingraham K L, et al. The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer's disease[J]. Neurobiol Aging, 2015, 36(11): 2995-3007. |